Bayer Kogenate FS

Attention: Your browser does not support Javascript, or Javascript support has been disabled. This web site utilizes the latest Internet technology, and in order to experience the full functionality of this web site you will need to ensure that Javascript is enabled.






























	General Conditions of Use Privacy Statement Imprint

	This website is intended for U.S. Audiences Only.

	© 2008 Bayer HealthCare LLC BAYER, the Bayer Cross, and Kogenate are registered trademarks of Bayer BIO-SET is a trademark of Biodome SAS

En Español

EN BAYER, NUESTRO COMPROMISO CON LA HEMOFILIA ES PROFUNDO
Bayer ha estado comprometida con el tratamiento de la hemofilia A desde el comienzo de la década de 1970. Ese compromiso se extiende hasta el presente. Nuestro objetivo sigue siendo fomentar la seguridad, la eficacia y la comodidad del tratamiento a fin de prolongar y mejorar la vida de las personas con hempfilia A. Pero nuestro compromiso no se limita a la ciencia y la innovación. También estamos dedicados a proveer herramientas y apoyo a los pacientes, las familias y los profesionales de la salud para que comprendan y controlen mejor la hemofilia A.

[Bayer has been committed to the treatment of hemophilia A since 1970 and this commitment extends to the present. Our objective is to promote the safety, efficacy, and convenience of treatment in order to prolong and improve the life of the people with hemophilia. But our commitment is not limited to science and innovation. We are also dedicated to providing tools and support to patients, families, and healthcare professionals so that they can understand and better manage the treatment of hemophilia A.]

La reacción adversa más frecuentemente descrita fueron las reacciones locales en el lugar de la inyección. Una hipersensibilidad conocida a la proteína del ratón o hámster podría constituir una contraindicación al uso de Kogenate FS. Por favor, lea el prospecto completo en www.kogenatefs.com

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.